Young men and minority patients with early-onset CRC in urban areas face higher CVD death risk, challenging assumptions about ...

Identification of fibroids on ultrasound can prematurely close evaluation, despite frequent co-existence and a ...

Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know ...

Datopotamab deruxtecan is now a first-line targeted therapy for immunotherapy-ineligible metastatic TNBC, addressing the ~70% lacking actionable PD-L1 eligibility and historically limited to ...

Simple FNI labs pinpoint high‑mortality MASLD fibrosis in type 2 diabetes, challenging FIB‑4 and sharpening MASH liver ...

Training deficits in STS brachytherapy stem primarily from limited resident case exposure, despite broad perceived importance ...

The heart failure (HF) treatment landscape continues to evolve rapidly in 2026, with emerging evidence pointing toward a ...

Reproductive-care access remains unsettled as mifepristone telehealth/mail distribution is temporarily protected by the ...

Nirogacestat (Ogsiveo; Springworks Therapeutics) is a therapy used to treat desmoid tumors, rare but aggressive growths that ...

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...

USPSTF recommendations have statutory coverage implications under the ACA, mandating no-cost coverage for graded preventive services and directly shaping access to mammography, colorectal screening, ...

In an interview with The American Journal of Managed Care ® (AJMC ®) at the American Thoracic Society International ...